abstract |
The present invention relates to a therapeutic compound comprising : n- an agent that inhibits the activity of at least one gene selected from the group consisting of FOXS1, CREB5, HIC1, IRF7, POU2F2, STAT4, TCF4, and/or n- an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 for use in the prevention and/or treatment of fibrosis, hypertrophic scar or keloid. |